Dr. Eric Raymond

• 
  Cancer Spectrum: Cancer News - This Week's Headlines - [Cached Version]
  Published on: 5/31/2002    Last Visited: 2/9/2003  

  Eric Raymond, of the Institute Gustave-Roussy in Villejuif, France, and his colleagues treated 28 patients for 28 days with escalating doses of SU11248.Side effects of the drug included temporary skin and hair discoloration.The study will continue for another 6 months, Raymond said.
  
  For JNCI News articles on angiogenesis inhibitors, see "First Clinical Trials of Endostatin Yield Lukewarm Results", "Natural Compounds Show Antiangiogenic Activity", "Cutting Copper Curbs Angiogenesis, Studies Show", "Antiangiogenesis Drugs Target Specific Cancers, Mechanisms", and "Angiogenesis Research Is on Fast Forward". Rapamycin, an immunosuppressive drug that organ transplant recipients take to prevent tissue rejection, may boost the effectiveness of radiotherapy in certain cancers, researchers reported at the meeting.Rapamycin works by blocking the activity of a protein called mTOR, which is involved in cancer cell survival and proliferation.Jann Sarkaria, of the Mayo Clinic in Rochester, Minn., and colleagues showed that in mouse models of glioblastoma treated with a combination of rapamycin and radiotherapy, tumor regrowth was delayed by 19 days.Sarkaria noted that the next step will be to test the combination in patients with glioblastoma and lung cancer, two cancers known to overexpress the mTOR protein.

• 
  CancerSource.com News - [Cached Version]
  Published on: 10/26/2001    Last Visited: 6/16/2005  

  The medicine, called Aplidine, was found to be effective in early Phase I studies involving 162 patients with thyroid, colorectal, kidney, neuroendocrine and skin cancers, Eric Raymond of the Institut Gustave Roussy, Villejuif, France, told the European Cancer Conference.
  ...
  Two thirds of the world's life forms live in the sea and only a few have been cultivated for use as possible medicines," Raymond said.

• 
  Cancer - Second Zeltia Drug Shows Cancer Promise - [Cached Version]
  Published on: 10/22/2001    Last Visited: 5/1/2002  

  The medicine, called Aplidine, was found to be effective in early Phase I studies involving 162 patients with thyroid, colorectal, kidney, neuroendocrine and skin cancers, Eric Raymond of the Institut Gustave Roussy, Villejuif, France, told the European Cancer Conference.
  
  The early studies were designed to identify the most efficacious doses in patients with advanced disease and further extensive clinical trials are needed before the benefits of the experimental drug are proven.
  
  Like Zeltia's most advanced anti-cancer drug, ET 743, Aplidine is derived from a sea squirt, a sponge-like creature that grows in clusters in the Mediterranean.
  
  In recent years some 3,000 new compounds from marine sources have been described by scientists, some of which appear to be potent chemicals capable of killing tumours or inhibiting their growth.
  
  ...
  Two thirds of the world's life forms live in the sea and only a few have been cultivated for use as possible medicines," Raymond said.
  
  Zeltia, which has carved out a niche as a specialist in drugs from the sea, in August signed Europe's second biggest biotech marketing deal ever for ET 743 with US healthcare giant Johnson & Johnson, worth more than $100 million.
  
  "Reuters content is the intellectual property of Reuters Limited.Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters.Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon."Send this article to a friend

• 
  For Immediate Release - [Cached Version]
  Published on: 11/16/1999    Last Visited: 6/19/2004  

  This is a unique mechanism of action for an anticancer agent," explained Eric Raymond, M.D., senior investigator and associate professor of oncology at the Institut Gustave Roussy in Villejuif, France."If these preliminary results are confirmed in future observations, this may represent a new and safer treatment for cancer patients."
  
  The results were presented by Jerome Alexandre, a physician-in-training and researcher with Dr. Raymond, who received an AACR Young Investigator Scholar Award, bestowed on predoctoral students, postdoctoral fellows, and physicians-in-training for outstanding abstracts.

• 
  Lifegoals/Story - [Cached Version]
  Published on: 3/19/2002    Last Visited: 4/18/2002  

  "This is an important first clinical step in determining the future role of irofulven in combination with platinum agents, like cisplatin, which have exhibited broad utility in the treatment of solid tumors," said Dr. Eric Raymond, Head of the Clinical Pharmacology Unit in the Department of Medicine at Institut Gustave Roussy in Villejuif, France, and principal investigator for MGI's trial."While irofulven and cisplatin are both DNA-interactive agents, they feature contrasting mechanisms of anti-tumor action.Preclinical studies of the drugs in combination have demonstrated synergistic activity and an absence of cross-resistance in common drug-resistant cell lines.The clinical anti-tumor effect of the irofulven-cisplatin combination may be synergistic as well."

• 
  MGI PHARMA Investor Relations - [Cached Version]
  Published on: 3/19/2002    Last Visited: 1/31/2005  

  "This is an important first clinical step in determining the future role of irofulven in combination with platinum agents, like cisplatin, which have exhibited broad utility in the treatment of solid tumors," said Dr. Eric Raymond, Head of the Clinical Pharmacology Unit in the Department of Medicine at Institut Gustave Roussy in Villejuif, France, and principal investigator for MGI's trial.

• 
  Novel anti-cancer agent shows minimal side effects... - [Cached Version]
  Published on: 11/17/1999    Last Visited: 8/14/2000  

  This is a unique mechanism of action for an anti-cancer agent, explained Eric Raymond, M.D., senior investigator and associate professor of oncology at the Institut Gustave Roussy in Villejuif, France.If these preliminary results are confirmed in future observations, this may represent a new and safer treatment for cancer patients..
  
  The results were presented by Jerome Alexandre, a physician-in-training and researcher with Dr. Raymond, who received an AACR Young Investigator Scholar Award, bestowed on predoctoral students, postdoctoral fellows, and physicians-in-training for outstanding abstracts.

• 
  Pancreatica News Abstracts Archives - MGI Pharma... - [Cached Version]
  Published on: 10/8/2001    Last Visited: 7/12/2002  

  "This is an important first clinical step in determining the future role of irofulven in combination with platinum agents, like cisplatin, which have exhibited broad utility in the treatment of solid tumors," said Dr. Eric Raymond, Head of the Clinical Pharmacology Unit in the Department of Medicine at Institut Gustave Roussy in Villejuif, France, and principal investigator for MGI's trial."While irofulven and cisplatin are both DNA-interactive agents, they feature contrasting mechanisms of anti-tumor action.Preclinical studies of the drugs in combination have demonstrated synergistic activity and an absence of cross-resistance in common drug-resistant cell lines.The clinical anti-tumor effect of the irofulven-cisplatin combination may be synergistic as well."

• 
  PharmaMar - News - News Release - [Cached Version]
  Published on: 10/24/2001    Last Visited: 5/9/2008  

  The results presented by Doctor Eric Raymond of the Institut Gustave Roussy (Villejuif, France) regarding phase I clinical trials on over 200 patients with advanced cancer revealed good tolerability, with no signs of hematologic toxicity, alopecia or mucositis.

• 
  Red Wing Republican Eagle - [Cached Version]
  Published on: 11/20/2002    Last Visited: 11/20/2002  

  The drug reduced tumors by half in several patients, which is a "very impressive response rate" considering that all these patients had failed on other cancer drugs and were terminally ill, Eric Raymond of Institut Gustave Roussy in Villejuif, France and principal investigator in the trial, told United Press International.Raymond presented the preliminary results of the study at the Symposium on Molecular Targets and Cancer Therapeutics sponsored by the European Organization for Research and Treatment of Cancer, the National Cancer Institute and the American Association for Cancer Research.
  
  "The patients are getting much better," Raymond said.The patients in the trial had "huge tumors" that caused pain, fatigue, weight loss and other complications due to the tumor pressing on vital organs, he said."When you shrink the tumor by more than 50 percent you are relieving much of the symptoms and usually the patient tells you 'I am feeling better, I have less pain, I am not fatigued.'"
  
  Raymond's team has not seen tumors disappear completely but that could happen as the study is not yet complete, he said, adding the trial is expected to conclude in May or June.
  
  So far, the team has treated 28 patients who had any kind of solid tumor cancers -- of the lung, kidney, breast, colon and skin.All the patients had failed on at least three previous therapies considered standard care for their type of cancer.
  
  Six of the patients experienced a tumor shrinkage of more than 50 percent, Raymond said.The main side effects were fatigue, turning the skin a golden color and turning the hair white because the drug interferes with pigment production.Hair and skin color return to normal when the drug is stopped.
  
  Another concern is the drug might work too well, Raymond said.It can kill the tumor faster than the body can repair the resulting hole, which can lead to infection or other complications."The compound is very powerful ... so we have to be very careful not to make it too efficient too rapidly," he said.Raymond's team is working to develop the right dose and regimen to prevent that from happening.
  
  He added the side-effect profile of the compound is better than current chemotherapy drugs used to treat cancer, which can cause severe toxicity in patients.
  
  Despite the promising results, Raymond urged for tempered enthusiasm.This trial is the first step in assessing the utility of the drug and it is designed to primarily look at safety not efficacy, he said.A number of anti-angiogenic agents have appeared promising but "then they never prove to be beneficial" when used in patients, he said."I don't want to give too much expectation."

Page:  1 2